INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA

Core Viewpoint - A class action lawsuit has been filed against Cassava Sciences, Inc. regarding allegations of securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves Cassava and certain officers and/or directors, with a deadline of February 10, 2025, for investors to request appointment as Lead Plaintiff [2]. - Investors who purchased or acquired Cassava securities during the Class Period are encouraged to contact Pomerantz LLP for participation [1][2]. Group 2: Company Performance - On November 25, 2024, Cassava announced that its drug simufilam failed to meet all pre-specified endpoints in a Phase 3 study for treating mild-to-moderate Alzheimer's disease [3]. - Following the announcement, Cassava's stock price plummeted by $22.19 per share, a decrease of 83.78$4.30 per share [4]. Group 3: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering billions in damages for class members [5].